



## RET Antibody [clone RET/2599] (V8055)

Catalog No.	Formulation	Size
V8055-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V8055-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V8055SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

### Bulk quote request

<b>Availability</b>	1-3 business days
<b>Species Reactivity</b>	Human
<b>Format</b>	Purified
<b>Host</b>	Mouse
<b>Clonality</b>	Monoclonal (mouse origin)
<b>Isotype</b>	Mouse IgG2b, kappa
<b>Clone Name</b>	RET/2599
<b>Purity</b>	Protein G affinity chromatography
<b>UniProt</b>	P07949
<b>Applications</b>	ELISA (order BSA-free Format For Coating) :
<b>Limitations</b>	This RET antibody is available for research use only.





SDS-PAGE analysis of purified, BSA-free RET antibody (clone RET/2599) as confirmation of integrity and purity.

## Description

The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney. Alterations in RET gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease.

## Application Notes

Optimal dilution of the RET antibody should be determined by the researcher.

## Immunogen

A recombinant human partial protein (amino acids 702-848) was used as the immunogen for this RET antibody.

## Storage

Store the RET antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).